NECLIFE

The stock has been placed in Additional Surveillance Measure (ASM) list LTASM - I (13).

Nectar Lifesciences Ltd.

NSE: NECLIFE

BSE: 532649

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

10.13-0.4 (-3.98%)

9 Oct, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

21.1 / 100

Value Score

10.0 / 100

Price Momentum Score

25.6 / 100

QVM Score

5.0 / 100

Key Metrics

Market Cap

196.79

P/E (TTM)

-0.80

P/B

0.34

P/S (TTM)

31.98

EV/EBITDA

CAPE (5Y)

ROE (TTM)

-46.16

ROCE (TTM)

-23.67

ROA (TTM)

-26.61

Avg 3Y ROE

Earnings 3Y CAGR

-131.63

Sales 3Y CAGR

-84.04

Sales 5Y CAGR

-66.86

Debt/Equity

0.00

Consensus TP

Strong Buy %

Promoter Holding

51.84

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Nectar Lifesciences Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Stock is cheap and PE TTM is at a discount to industry median

PE TTM of -0.8 indicates that the stock is cheap on a standalone basis. Discount to industry median P/E is decent at -102.54%

What is P/E Ratio?

Median: 31.48

Value -0.8

-0.8734.68

Low and declining Debt to Equity

The company has low Debt to Equity of 0.0 as on 30 Jun 2026 and Debt to Equity decreased by 0.61 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 5 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Weak price momentum

Price Momentum score of 25.6 indicates that the stock has weak price momentum. Research has shown that stocks with lower momentum continue to underperform in the near term

What is Price Momentum score?

25.6 / 100

Low and declining ROE

The company reported low ROE of -46.16% for 12-month ended 30 Jun 2026 and ROE declined by -3493 bps from 1 year ago

What is ROE (FY)?

Low and declining operating margin

The company reported low operating margin of -1417.47% for 12-month ended 30 Jun 2026 and operating margin declined by -140544 bps from 1 year ago

What is Operating profit margin?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of -99.61% for 12-month ended 30 Jun 2026 and the growth was 110.29 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 10.68

Value -99.61

-99.6111701.8

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -164.35% for 12-month ended 30 Jun 2026 and the growth was 171.8 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Company's earnings are of low quality

Earnings quality score of 28.3 indicates that the company's earnings are of low quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

28.3 / 100

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Not enough talking points with neutral stance

Financial Snapshot

See detailed analysis

Multi-year trends for Nectar Lifesciences Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Nectar Lifesciences Ltd. Shareholding Pattern

Quarterly breakdown of Nectar Lifesciences Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	44.53	44.53	44.53	44.91	44.91	51.84	51.84
Indian Promoter	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	55.80	44.53	44.53	44.53	44.91	44.91	51.84	51.84
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	2.90	2.90	2.90	2.62	2.62	2.62	2.46	1.52	1.67	1.49	16.14	16.01	16.09	16.01	16.03	16.13	16.99	16.63	3.26	0.75	1.80	0.96	0.69	6.36	4.63	4.25
Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
FII	2.90	2.90	2.90	2.62	2.62	2.62	2.46	1.52	1.67	1.49	16.12	15.99	16.07	16.00	16.02	16.12	16.98	16.60	3.24	0.73	1.65	0.82	0.62	0.52	0.60	0.50
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.13	0.13	0.04	5.82	4.01	3.73
Non-Institution	41.30	41.30	41.30	41.58	41.58	41.58	41.74	42.68	42.53	42.72	28.06	28.19	28.11	28.18	28.16	28.06	27.21	27.57	40.94	54.72	53.67	54.50	54.41	48.73	43.52	43.90
Bodies Corporate	16.95	16.94	16.69	16.71	16.70	16.75	17.24	16.83	16.41	16.44	1.61	1.54	1.57	1.55	1.68	1.77	1.59	1.45	7.54	10.98	6.97	5.30	4.84	4.30	3.67	2.94
Others (incl. Retail) No. of shareholders	24.35 39,760	24.36 47,022	24.61 46,907	24.87 46,538	24.88 47,201	24.83 53,087	24.50 54,884	25.85 55,837	26.12 63,795	26.28 63,697	26.45 62,738	26.65 64,228	26.54 62,688	26.63 61,389	26.48 60,093	26.29 60,567	25.62 59,749	26.12 58,044	33.40 66,463	43.74 69,110	46.70 68,894	49.20 71,631	49.57 76,153	44.43 77,823	39.85 74,557	40.96 73,568

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Nectar Lifesciences Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
RAMAN GOYAL Promoter Group	December-2024	Market Purchase (Acquisition) 19th Dec 2024	0.00 %	₹ 44.37	4.00 lac	₹ 1.77 cr

Corporate Actions

History of Nectar Lifesciences Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Others
Ex-date: 24th Dec 2025Announced on: 3rd Dec 2025
"On Market Tender Offer."
Dividend₹ 0.05/share
Record date: 14th Sep 2020Ex-date: 11th Sep 2020
Announced on: 29th Jul 2020
Dividend₹ 0.05/share
Record date: 21st Sep 2019Ex-date: 19th Sep 2019
Announced on: 25th May 2019
Dividend₹ 0.05/share
Record date: 21st Sep 2018Ex-date: 19th Sep 2018
Announced on: 28th May 2018
Dividend₹ 0.05/share
Record date: 21st Sep 2017Ex-date: 20th Sep 2017
Announced on: 27th Jun 2017

Company Profile

Overview of Nectar Lifesciences Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Nectar Lifesciences Limited is an India-based pharmaceutical company. The Companys business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged...

Key personnel

Mr. Amit Chadah

Chief Executive Officer

Mr. Sanjaymohan Singh Rawat

Compliance Officer, Company Secretary

Mr. Sanjiv GoyalD

Executive Chairman of the Board, Managing Director

Mr. Sushil KapoorD

Additional Director( Whole-Time Director), Director (Finance)

Dr. Kuldip Kumar BhasinD

Independent Non-Executive Director

Dr. Indu Pal Kaur, Ph.D.D

Independent Non-Executive Director

Dr. Rupinder TewariD

Independent Non-Executive Director

Dr. Rupinder TewariD

Independent Non-Executive Director

Incorporated on

27 Jun 1995

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

111

IPO date

19 Jul 2005

Free Float

8,61,32,179

Website

https://www.neclife.com/

Phone no.

+911723047777

Address

Sco 38-39,, Sector 9-D, CHANDIGARH, 160009, India

Frequently Asked Questions

What is the current share price of Nectar Lifesciences Ltd.?

The current share price of Nectar Lifesciences Ltd. is ₹ 10.13 as of 9 Oct 2026.

What is the market capitalisation of Nectar Lifesciences Ltd.?

The market capitalisation of Nectar Lifesciences Ltd. stands at ₹ 196.79 Cr.

What is the PE ratio of Nectar Lifesciences Ltd.?

The Price-to-Earnings (PE) ratio of Nectar Lifesciences Ltd. is -0.80 as of the latest trailing twelve months data.

What is the ROE and ROCE of Nectar Lifesciences Ltd.?

Nectar Lifesciences Ltd. has a Return on Equity (ROE) of -46.16% and a Return on Capital Employed (ROCE) of -23.67% as per the latest financial reports.

What is the 52-week high and low of Nectar Lifesciences Ltd.?

The 52-week high of Nectar Lifesciences Ltd. is - and the 52-week low is -.

What is the dividend yield of Nectar Lifesciences Ltd.?

The dividend yield of Nectar Lifesciences Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Nectar Lifesciences Ltd.?

Foreign Institutional Investors (FII) hold 0.50%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 40.96% of Nectar Lifesciences Ltd. shares.

What sector does Nectar Lifesciences Ltd. belong to?

Nectar Lifesciences Ltd. operates in the Healthcare sector.

What is the beta of Nectar Lifesciences Ltd.?

The beta of Nectar Lifesciences Ltd. is 1.02, indicating its price volatility relative to the broader market. Over the past 1 year, Nectar Lifesciences Ltd. has delivered an absolute return of -29.21%.

What is the RSI of Nectar Lifesciences Ltd.?

The 14-day Relative Strength Index (RSI) of Nectar Lifesciences Ltd. is 34.98, placing it approaching oversold territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Nectar Lifesciences Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Nectar Lifesciences Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Corporate Actions

Company Profile

Stock Analysis